One-year rehospitalisation after percutaneous coronary intervention: a retrospective analysis



Kirstine Nørregaard Hansen¹, MD; Kristoffer Bendix¹, MD; Lisbeth Antonsen¹, MD, PhD; Karsten Tange Veien¹, MD; Michael Mæng², MD, PhD; Anders Junker¹, MD, PhD; Evald Høj Christiansen², MD, PhD; Johnny Kahlert³, MSc; Christian Juhl Terkelsen², MD, DMSci, PhD; Lotte Brix Christensen³, MSc; Christian Oliver Fallesen¹, MD; Hans Erik Bøtker², MD, DMSci, PhD; Lisette Okkels Jensen^{1*}, MD, DMSci, PhD

1. Department of Cardiology, Odense University Hospital, Odense, Denmark; 2. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark

KEYWORDS

- ACS/NSTE-ACS
- NSTEMI
- stable angina
- STEMI

Abstract

Aims: The aim of the study was to evaluate the incidence and causes of rehospitalisation within one year after percutaneous coronary intervention (PCI) in a country where the National Health Service provides universal tax-supported healthcare, guaranteeing residents free hospital access.

Methods and results: Between January 2010 and September 2014, 17,111 patients were treated with PCI in two University Hospitals in Western Denmark. Patients who were readmitted within one year after PCI were identified. The overall one-year readmission rate was 50.4%. The cause was angina/myocardial infarction (MI) in 4,282 patients (49.7%), and other reasons in 4,334 (50.3%). Predictors of angina/MI-related readmissions were female gender (odds ratio [OR] 1.15, 95% confidence interval [CI]: 1.07-1.25), diabetes (OR 1.14, 95% CI: 1.04-1.26), age (per 10-year increase) (OR 0.86, 95% CI: 0.83-0.88), and indication for index PCI (stable angina pectoris as reference): ST-segment elevation myocardial infarction (OR 1.34, 95% CI: 1.23-1.47) and non-ST-segment elevation myocardial infarction (OR 1.18, 95% CI: 1.08-1.29). Predictors for other readmissions were female gender (OR 1.09, 95% CI: 1.01-1.18), diabetes (OR 1.29, 95% CI: 1.18-1.42), age (OR 1.30, 95% CI: 1.26-1.34) and Charlson comorbidity index \geq 3 (OR 3.03, 95% CI: 2.71-3.27).

Conclusions: In an unselected patient cohort treated with PCI, half of the patients were rehospitalised within one year, highlighting the impact of comorbidity in patients with ischaemic heart disease.

**Corresponding author: Department of Cardiology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark. E-mail: okkels@dadlnet.dk*

DOI: 10.4244/EIJ-D-17-0080C

Abbreviations

ACS	acute coronary syndrome
CABG	coronary artery bypass graft
CCI	Charlson comorbidity index
CHF	chronic heart failure
CI	confidence interval
IHD	ischaemic heart disease
MI	myocardial infarction
NSTEMI	non-ST-segment elevation myocardial infarction
OR	odds ratio
PCI	percutaneous coronary intervention
SAP	stable angina pectoris
STEMI	ST-segment elevation myocardial infarction
WDHR	Western Denmark Heart Registry

Introduction

Ischaemic heart disease (IHD) is a progressive condition which can lead to an increased risk of mortality and morbidity¹. It is a common and burdening condition for both the patients and the healthcare system^{2.3}. Initially, patients with coronary artery disease have a relatively low mortality rate (1.2-2.4%), but the individual prognosis is highly influenced by various factors, such as baseline characteristics, previous myocardial infarction (MI), and comorbid diseases such as diabetes and chronic kidney disease⁴.

Half of the patients presenting with IHD and acute coronary syndrome (ACS) suffer from chronic comorbidities, which may have a major influence on a patient's outcome both during and after hospitalisation^{1,5}. It is important to bear in mind various factors such as age, comorbidities and physical condition, when reperfusion with thrombolysis or revascularisation with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) is considered^{4,5}. PCI is a common and low-risk procedure with a poorly described readmission pattern⁶.

Thirty-day readmission rates after PCI range from 8.0% to 17.9% with a majority of cardiac-related reasons for rehospitalisation, but long-term readmission rates and non-cardiac reasons are poorly described⁶⁻¹⁰. It is difficult to predict long-term readmission, as knowledge of this health issue is limited, but individual health condition has a great influence on the risk of readmission, and needs to be considered when discussing this issue^{7,11,12}. It is important to understand the reasons for readmission to improve patient outcome and prevent readmissions. To shed light on the impact of comorbidity in a progressive condition such as IHD, a long-term investigation of risk factors is necessary.

The purpose of this study was to investigate the one-year readmission rate after PCI and to evaluate predictors for angina/ MI-related and other rehospitalisations in a country with free access to healthcare.

Methods STUDY POPULATION

The study was conducted using Western Denmark's healthcare databases, which cover the region's entire population of approximately 3.0 million inhabitants (55% of the Danish population). A detailed description of the databases has been reported previously¹³. The Danish National Health Service provides universal tax-supported healthcare, guaranteeing residents free access to general practitioners and hospitals. We used the Western Denmark Heart Registry (WDHR) to identify all PCI procedures performed from 1 January 2010 up to 30 September 2014, at Odense University Hospital and Aarhus University Hospital. The study protocol was approved by The Danish Data Protection Agency (2012-41-0164).

All Danish citizens can be tracked in the healthcare system and national registries. The Danish Civil Registration System has kept electronic records on gender, birth date, residence, and emigration date since 1968, and characteristics of all non-psychiatric inpatient admissions since 1977 with daily updates¹⁴. The 10-digit civil registration number assigned at birth and used in all registries allows accurate record linkage¹⁵. The Danish Civil Registration System provided vital status data for our study participants and minimised loss to follow-up.

DATA ANALYSIS

PCI procedures were linked to the Danish Civil Registration System using the 10-digit civil registration number, which made it possible to list the readmissions within one year, and to track the diagnoses given during the readmission, specified using ICD-10 coding. Several diagnoses were given during the hospitalisation, but only one action diagnosis was given at discharge. The action diagnosis was used as the reason for readmission. Admissions within two days of the index procedure were interpreted as transfer between departments and were not included as readmissions in the data set. Patients who were readmitted several times within one year were only included once in the data set with the first given diagnosis. Only hospital readmissions were included.

For each patient, data on all diagnoses from the Danish National Registry of Patients were obtained. Comorbidity scores were computed using the Charlson comorbidity index (CCI)¹⁶, which covers 19 major disease categories, including diabetes mellitus, heart failure, cerebrovascular diseases, and cancer. The CCI is used to estimate risk of death in patients with comorbid diseases. The CCI value is a weighted summary of the diagnoses and weights the number and seriousness of comorbid diseases calculated on the basis of one-year mortality associated with each disease in the original Charlson data set¹⁶. A modified CCI was used, as diabetes mellitus was considered a separate confounder and removed from the CCI. Reasons for readmission were recorded and categorised.

STATISTICAL ANALYSIS

Contingency tables were created for the main study variables characterising patients readmitted to hospital and not readmitted after PCI. The group of readmitted patients was further divided into patients with and without diagnoses of IHD. The follow-up period was 365 days after PCI. Statistical comparisons were undertaken for the two readmitted patient groups versus the non-readmitted group, using t-tests for continuous variables and the χ^2 test for categorical variables. For readmitted patients, the most frequently occurring diagnosis was identified during readmission and up to one year after PCI. Kaplan-Meier curves were constructed to estimate the probability of readmission within 365 days from the PCI and compared across indications for PCI (stable angina pectoris [SAP], STEMI, NSTEMI and other), comorbidities (using CCI ten years prior to PCI), diabetes mellitus and gender with log-rank tests. Eventually, potential risk factors for readmission after PCI were analysed using logistic regression: the indication for PCI, comorbidities, diabetes mellitus together with age and gender. All data analyses were carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results

STUDY POPULATION

A total of 18,025 patients were treated with PCI at one of the two participating PCI centres between January 2010 and September 2014. Of these, 158 patients were foreign citizens, 14 patients emigrated, 566 patients died before hospital discharge and 176 had missing admission dates in the database; these were all excluded from the analysis (Figure 1). Thus, the final study cohort consisted of 17,111 patients. The readmissions included both acute readmissions and staged revascularisation. Of the included patients, 8,616 patients (50.4%) were readmitted to the hospital within 365 days after the index PCI procedure. The all-cause 30-day readmission rate was 14.9%. The majority of patients were readmitted within the first month (Figure 2).

CHARACTERISTICS OF READMITTED PATIENTS

The clinical characteristics at baseline are shown in **Table 1**. Compared with patients who were not readmitted, females, smokers




Figure 2. *Timing of all-cause rehospitalisation: non-cumulative frequency within one year:*

and diabetics were more likely to be readmitted for angina/MI. However, patients readmitted due to other reasons were more likely to be elderly, female, have a family history of IHD, hypertension, hypercholesterolaemia, diabetes mellitus, and have higher levels of creatinine, compared to patients who were not readmitted. Patients with previous PCI, or CABG, or MI patients with comorbidities, with a longer stay at index hospitalisation, and patients with multivessel disease were more likely to be readmitted within 365 days, no matter the reason. The frequency of each component of the modified CCI is illustrated in **Figure 3**. The most common comorbidities were MI, peripheral vascular disease and cerebrovascular disease.




Figure 1. Flow chart of enrolled patients.

Table 1. Baseline characteristics of patients readmitted to hospital within 365 days after a PCI procedure (N=17,111).

		All patients (N=17,111)	Readmission related to angina/MI (N=4,282)	Other readmissions (N=4,334)	Not readmitted (N=8,495)	<i>p</i> -value (comparing other readmissions vs. patients not readmitted)	<i>p</i> -value (comparing readmission related to angina/MI vs. patients not readmitted)
Age, years at PCI		66.4±11.7	64.7±11.9	69.8±11.4	65.5±11.5	<0.0001	0.0011
Male		12,426 (72.6)	3,060 (71.5)	3,000 (69.2)	6,366 (74.9)	<0.0001	<0.0001
BMI, kg/m²		27.1±5.2	27.3±5.2	26.8±5.3	27.2±5.2	0.0001	0.4974 (NS)
Systolic blood	pressure, mmHg	136.0±23.8	134.7±23.0	134.9±24.7	137.1±23.6	<0.0001	<0.0001
Diastolic bloo	d pressure, mmHg	75.0±13.5	74.8±13.5	73.4±14.0	76.0±13.2	<0.0001	<0.0001
Days between	PCI and readmission	108.6±102.0	100.6±100.8	116.5±102.6			
Creatinine, µn	nol/L	92.8±105.6	88.6+59.6	106.3±88.3	87.7±128.6	<0.0001	0.6423 (NS)
Family history	of IHD	7,652 (44.7)	1,887 (44.1)	1,961 (45.2)	3,804 (44.8)	<0.0001	0.3164 (NS)
Current smoke	er	5,041 (29.5)	1,360 (31.8)	1,164 (26.9)	2,521 (29.6)	<0.0001	0.0093
Year of	2010	3,708 (21.7)	979 (22.9)	931 (21.5)	1,798 (21.2)		
intervention	2011	3,783 (22.1)	1,024 (23.9)	911 (21.0)	1,848 (21.8)		
	2012	3,643 (21.3)	918 (21.4)	941 (21.7)	1,784 (21.0)	0.2425 (NS)	<0.0001
	2013	3,505 (20.5)	797 (18.6)	941 (21.7)	1,767 (20.8)		
	20141	2,472 (14.4)	564 (13.2)	610 (14.1)	1,298 (15.3)		
Blood pressur	e-lowering therapy	9,037 (52.8)	2,194 (51.2)	2,572 (59.3)	4,271 (50.3)	<0.0001	0.495 (NS)
Lipid-lowering	g therapy	9,043 (52.8)	2,213 (51.7)	2,465 (56.9)	4,365 (51.4)	<0.0001	0.1739 (NS)
Diabetes mell	itus	2,673 (15.6)	708 (16.5)	843 (19.5)	1,122 (13.2)	<0.0001	<0.0001
Previous CAB	Previous CABG		407 (9.5)	528 (12.2)	632 (7.4)	<0.0001	<0.0001
Previous PCI		2,930 (17.1)	770 (18.0)	792 (18.3)	1,368 (16.1)	0.0024	0.0008
Previous MI		2,778 (16.2)	701 (16.4)	851 (19.6)	1,226 (14.4)	<0.0001	0.0003
Number of	1 vessel	7,525 (44.0)	1,665 (38.9)	1,795 (41.4)	4,065 (47.9)		<0.0001
diseased vessels	2 vessels	3,191 (18.6)	1,036 (24.2)	760 (17.5)	1,395 (16.4)	<0.0001	
1000010	3 vessels	1,760 (10.3)	586 (13.7)	543 (12.5)	631 (7.4)		
	Diffuse disease	25 (0.1)	8 (0.2)	3 (0.1)	14 (0.2)		
Indication for PCI	ST-segment elevation myocardial infarction	4,954 (29.0)	1,419 (33.1)	1,071 (24.7)	2,464 (29.0)		<0.0001
	Non-ST-segment elevation myocardial infarction or unstable angina	5,095 (29.8)	1,308 (30.5)	1,327 (30.6)	2,460 (29.0)	<0.0001	
	Stable angina	6,433 (37.6)	1,460 (34.1)	1,625 (37.5)	3,348 (39.4)		
	Other	629 (3.7)	95 (2.2)	257 (5.9)	223 (2.6)		
10-year	0	9,083 (53.1)	2,330 (54.4)	1,636 (37.7)	5,117 (60.2)		<0.0001
Charlson comorbidity index ²	1-2	6,074 (35.5)	1,500 (35.0)	1,797 (41.5)	2,777 (32.7)	<0.0001	
	≥3	1,954 (11.4)	452 (10.6)	901 (20.8)	601 (7.1)		
Duration of	0-3 days	12,024 (70.3)	2,896 (67.6)	2,791 (64.4)	6,337 (74.6)	<0.0001	<0.0001
index hospitalisa-	4-7 days	3,661 (21.4)	1,122 (26.2)	912 (21.0)	1,627 (19.2)		
tion	>7 days	1,426 (8.3)	264 (6.2)	631 (14.6)	531 (6.3)		
Days from	2-30 days	2,558 (14.9)	1,315 (30.7)	1,151 (26.6)	- ()	0.0001	<0.0001
PCI to readmission	31-365 days	6,150 (35.9)	2,967 (69.3)	3,183 (73.4)	- ()	<0.0001	
Died ≤365 day	vs after PCI	745 (4.4)	129 (3.0)	473 (10.9)	143 (1.7)		

Data are presented as mean±SD, or n (%). ¹ Inclusion of patients in 2014 was only 9 months from January-September. ²A modified Charlson comorbidity index was used, as diabetes mellitus was considered a separate confounder and removed from the original index. BMI: body mass index; CABG: coronary artery bypass graft surgery; IHD: ischaemic heart disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; SD: standard deviation

REASONS FOR READMISSION

Reasons for readmission were various and are shown in **Table 2**. Of all the 8,616 patients readmitted, 4,282 patients (49.7%) were

readmitted on suspicion of angina/MI within 365 days after the index PCI procedure. The diagnoses defining angina/MI are shown in **Table 2**. The remaining 4,334 patients (50.3%) were readmitted




Figure 3. Frequency of each component of the modified Charlson comorbidity index. Note that diabetes is considered a separate confounder and is excluded from the index.

due to other indications. The most common angina/MI-related reasons for readmission were angina pectoris/chest pain (87.5%) and ACS (12.5%). ACS is defined by the action diagnosis: MI, unspecified, unstable angina, STEMI and NSTEMI. For patients readmitted for other reasons, heart failure was the most common cause (5.5%), followed by atrial fibrillation/flutter (5.3%), and abdominal pain (5.3%) (Table 2).

RISK OF READMISSION

The probability of readmission is illustrated in the Kaplan-Meier curves (Figure 4). The probability of being readmitted within 365 days increased with higher modified 10-year CCI, if the patients were diabetic or female, or if the PCI was performed due to an indication other than NSTEMI, STEMI or SAP.




Figure 4. *Kaplan-Meier cumulative event curves with 95% confidence limits for probability of readmission after PCI within a year as per various factors. A) Gender. B) Modified Charlson comorbidity index. C) Indication for percutaneous coronary intervention. D) Diabetes status.*

Table 2. Causes of readmission for the first readmission within365 days after PCI.

Angi	na/MI-related readmissions. N=4,282	
	Diagnosis	N (%)
1	Angina pectoris/chest pain	3,746 (87.5%)
2	Acute coronary syndromes	536 (12.5%)
Top 2	25 other readmissions. N=4,334	
	Diagnosis	N (%)
1	Heart failure	240 (5.5%)
2	Atrial fibrillation/flutter	231 (5.3%)
3	Abdominal pain, cholecystitis, colitis, enteritis, pancreatitis, cholangitis and appendicitis	231 (5.3%)
4	Cancer	218 (5.0%)
5	Bleeding	201 (4.6%)
6	Sepsis/bacterial infections	194 (4.5%)
7	Pneumonia	191 (4.4%)
8	Arthritis, arthrosis and joint pains	171 (3.9%)
9	Fractures, lesions and contusion	167 (3.9%)
10	Valve disease	161 (3.7%)
11	Arrhythmia	157 (3.6%)
12	Peripheral vascular disease	154 (3.6%)
13	Dyspnoea/respiratory insufficiency	139 (3.2%)
14	Suspected condition	135 (3.1%)
15	Syncope	119 (2.7%)
16	Anaemia	118 (2.7%)
17	Kidney failure/disease	105 (2.4%)
18	Neurological symptoms	103 (2.4%)
19	Hypertension and other cardiac conditions	93 (2.1%)
20	Ischaemic stroke	89 (2.1%)
21	Chronic obstructive pulmonary disease	80 (1.8%)
22	Heart/valve transplantation	66 (1.5%)
23	Complication after other procedures	63 (1.5%)
24	Benign tumour	60 (1.4%)
25	Dehydration	50 (1.3%)
	Other	798 (18.4%)
MI: m	yocardial infarction; PCI: percutaneous coronary	intervention

A modified 10-year CCI \geq 3 was the strongest risk factor for other readmission (OR 3.0, 95% CI: 2.7-3.3, p<0.0001) **(Table 3)** but did not increase the risk for angina/MI patients. Patients presenting with NSTEMI and STEMI were at no greater risk of being readmitted for other reasons compared to patients with SAP, whereas patients with other indications for PCI had a 2.7-fold increased risk for other readmissions than those with stable angina. However, both NSTEMI and STEMI patients had a higher risk of angina/MI-related readmission compared to SAP, while other indications for PCI were associated with a lower likelihood of angina/ MI-related readmission. Older age was linked to a 1.3 times higher risk of other readmission but was associated with a lower likelihood of angina/MI-related readmission. Females and diabetic patients had a slightly higher risk of readmission in both groups.

ANGIOGRAM AND REVASCULARISATION

Of the 17,111 patients included in the study, 3,455 (20.2%) had new coronary angiography within 365 days after index PCI (**Table 4**). The coronary angiography was followed by PCI in

Table 4. Patients with new coronary angiography and revascularisation within 365 days. N=17,111.

Patients with new coronary angiography	3,455 (20.2%)	
Patients with new revascularisation		
Patients with PCI	1,247 (7.3%)	
Days since PCI	119±113.3	
Patients with CABG	166 (1.0%)	
Days since PCI	136±107.7	
Patients with staged* revascularisation		
Patients with staged* PCI	658 (3.8%)	
Days since PCI	37±47.6	
Patients with staged CABG	282 (1.6%)	
Days since PCI	78±57.0	
Data are presented as mean±SD, or n (%). *New PCI or CABG procedures after index PCI performed without new angiogram were interpreted as staged. CABG: coronary artery bypass graft surgery; PCI: percutaneous coronary intervention		

Table 3. Predictors of readmission.

Comparator	Readmissions related to	angina/MI	Other readmissions		
	Adjusted OR (95% CI)	<i>p</i> -value	Adjusted OR (95% CI)	<i>p</i> -value	
Female vs. male	1.152 (1.065-1.246)	0.0004	1.088 (1.005-1.178)	0.0375	
Yes vs. no	1.140 (1.035-1.256)	0.0078	1.293 (1.176-1.422)	<0.0001	
Per 10-year increase	0.855 (0.829-0.882)	<0.0001	1.297 (1.255-1.341)	<0.0001	
1-2 vs. 0	1.055 (0.976-1.140)	0.1799	1.655 (1.528-1.792)	<0.0001	
≥3 vs. 0	1.038 (0.920-1.171)	0.5467	3.026 (2.713-3.274)	<0.0001	
Other vs. SAP	0.624 (0.497-0.783)	<0.0001	2.705 (2.278-3.213)	<0.0001	
NSTEMI vs. SAP	1.180 (1.082-1.287)	0.0002	1.029 (0.943-1.122)	0.5271	
STEMI vs. SAP	1.347 (1.234-1.470)	<0.0001	1.039 (0.947-1.140)	0.4154	
	Female vs. male Yes vs. no Per 10-year increase 1-2 vs. 0 ≥3 vs. 0 Other vs. SAP NSTEMI vs. SAP	Comparator Adjusted OR (95% Cl) Female vs. male 1.152 (1.065-1.246) Yes vs. no 1.140 (1.035-1.256) Per 10-year increase 0.855 (0.829-0.882) 1-2 vs. 0 1.055 (0.976-1.140) ≥3 vs. 0 1.038 (0.920-1.171) Other vs. SAP 0.624 (0.497-0.783) NSTEMI vs. SAP 1.180 (1.082-1.287)	Adjusted OR (95% Cl) p-value Female vs. male 1.152 (1.065-1.246) 0.0004 Yes vs. no 1.140 (1.035-1.256) 0.0078 Per 10-year increase 0.855 (0.829-0.882) <0.0001	Comparator Adjusted OR (95% Cl) p-value Adjusted OR (95% Cl) Female vs. male 1.152 (1.065-1.246) 0.0004 1.088 (1.005-1.178) Yes vs. no 1.140 (1.035-1.256) 0.0078 1.293 (1.176-1.422) Per 10-year increase 0.855 (0.829-0.882) <0.0001	

Adjusted for all covariates. CCI: Charlson comorbidity index; CI: confidence interval; MI: myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; OR: odds ratio; SAP: stable angina pectoris; STEMI: ST-elevation myocardial infarction

1,247 patients (7.3%), and CABG in 166 patients (1.0%). Planned revascularisation was seen in 5.5% of the patients -658 (3.8%) received staged PCI, and 282 (1.6%) underwent staged CABG.

Discussion

The present study found that half of the patients undergoing PCI were readmitted within one year after the procedure. Half of the readmitted patients were rehospitalised on suspicion of angina/MI, and half were readmitted due to other causes. One in eight of the angina/MI patients was hospitalised due to ACS, and the rest were readmitted due to angina or angina-suspected events. The all-cause 30-day readmission rate was found to be 14.9%.

A recent published study⁸ found a lower 30-day readmission rate compared to ours (9.8% vs. 14.9%). Multiple aspects can influence the differing results. Firstly, data collection using WDHR combined with the Danish Civil Registration System made it possible to register all readmissions to every Danish hospital and not just the index hospital, thereby minimising loss to follow-up. Secondly, we included PCI centres with patient uptake from Western Denmark, which comprises both metropolitan and rural areas. Additionally, our study included patients from two of five PCI centres, thereby representing half of the Danish population. Furthermore, the patient's possibility of readmission did not depend on health insurance or income due to the free Danish healthcare system, thus resulting in a diverse population.

Our results confirmed that chest pain was the major reason for readmission within the first year after index PCI. Among patients presenting with IHD symptoms, the suspicion of ACS often results in diagnostic procedures such as coronary angiography. Occasionally, angiography was performed for diagnostic or research purposes during readmission, and repeat revascularisations were also performed as elective procedures at times. One fifth of the readmitted patients had a new angiogram, but only a minority required revascularisation treatment with repeat PCI (7.3%) or CABG (1.0%). In prior studies, approximately half of all readmitted patients underwent a repeat PCI within 30 days of readmission, but only a small percentage (10.5%) was due to acute MI6,17-19. Also, in these studies, both staged and acute PCI were encountered. It should be borne in mind that patients are at great risk of repeat revascularisation within the first month after index PCI - often a staged procedure - but this plays a small role in readmission treatment within 365 days²⁰.

In order to reduce the readmission rates after PCI, it should be taken into account that the patient's individual condition and health status appear to influence the outcome, more than the PCI procedure itself. IHD is a progressive disease that leads to an increased risk of both mortality and morbidity. Several variables influencing mortality - such as female sex, medical insurance, education and age - are not modifiable^{7,17,19}, but comorbidity may have a greater impact on one-year outcome than was previously expected. Our findings show that half of the patients were readmitted due to other reasons, e.g., infection, cancer, chronic obstructive pulmonary disease, diseased peripheral vessels, chronic heart failure

(CHF) and kidney failure. Patients with a CCI \geq 3 had a threefold increased risk of readmission for other reasons, whereas CCI played no significant role for patients readmitted with angina/MI. Furthermore, diabetes and old age increased the readmission risk significantly. Patients with an index indication for PCI other than SAP, STEMI or NSTEMI were at a 2.7-fold increased risk of readmission. This indication covers, for example, revascularisation in patients with arrhythmia, valve disease, cardiomyopathy and CHF with severely reduced ejection fraction. This group of patients is known to suffer from more comorbidities²¹. Comorbidity in IHD patients is associated with long-term mortality and renal disease, diabetes, peripheral vascular disease and chronic obstructive pulmonary disease in particular lead to higher mortality rates. These findings indicate that chronic medical conditions should be considered when investigating management of individual therapy, counselling and quality comparison to avoid readmission.

Long length of hospital stay was related to higher readmission rates for all readmissions, demonstrating that patients in need of no or limited healthcare after the procedure were less likely to be readmitted. Similar results have been presented in prior studies^{8,18}. These findings indicate that patients with comorbidities are at high risk for readmission and are particularly vulnerable after PCI procedures. This information can be used to advise the health system to be careful with treatment and discharge of patients with comorbid diseases, and to consider the benefits from close outpatient follow-up after the index PCI.

Limitations

Our study should be interpreted in the context of several potential limitations. Firstly, as previously discussed, we did not distinguish between patients who were readmitted more than once within a year; these patients were only included in the data set with their first readmission diagnosis. In addition, readmission within two days of the index procedure was interpreted as transfer between departments or hospitals during the index admission and was not included as a readmission in the data set, thereby risking losing very early, acute readmissions. Secondly, it was not possible to differentiate between patients who underwent coronary angiography for research purposes, or patients undergoing coronary angiography or PCI due to acute chest pain. Thirdly, principal diagnoses such as "chest pain", "chronic heart failure" and "ACS" are defined from several different diagnostic codes, which results in difficulties determining the actual reason for readmission. Finally, in our study, we present data from a population with free healthcare which are thereby not limited by economic aspects. It is unclear therefore to what extent our results can be generalised to other healthcare systems and hospitals.

Conclusions

In an unselected patient cohort treated with PCI, a substantial proportion of patients is readmitted within one year. The reasons for readmission fall into several broad categories with "chest pain" as the most common diagnosis. Even though one in five patients had new angiography, only a minority of the patients needed repeat revascularisation. Other reasons for rehospitalisations accounted for half of the readmissions with a large number of both cardiac and non-cardiac causes. Comorbidities were the strongest predictor of readmission and were associated with an increased risk of readmission, which highlights the impact of comorbidity in patients with IHD.

Impact on daily practice

In a country with free hospital access, half of the patients undergoing PCI were readmitted within one year after the procedure. Half of the readmitted patients were rehospitalised on suspicion of IHD, and half were readmitted due to non-IHD causes. This information can be used to advise the health system to be careful with treatment and discharge of patients with comorbid diseases, and to consider the benefits of close outpatient follow-up after index PCI.

Conflict of interest statement

L.O. Jensen has received research grants from Terumo, Biotronik, St. Jude Medical, and Biosensors to her institution. The other authors have no conflicts of interest to declare.

References

1. Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. *J Am Coll Cardiol*. 2004;43:576-82.

2. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. *Nat Rev Cardiol.* 2014;11:276-89.

3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet.* 2003;361: 13-20.

4. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J.* 2013;34:2949-3003.

5. Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, Puhan MA, Erne P; AMIS Plus Investigators. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. *Heart*. 2014;100:288-94.

6. Curtis JP, Schreiner G, Wang Y, Chen J, Spertus JA, Rumsfeld JS, Brindis RG, Krumholz HM. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. *J Am Coll Cardiol.* 2009; 54:903-7.

7. Khawaja FJ, Shah ND, Lennon RJ, Slusser JP, Alkatib AA, Rihal CS, Gersh BJ, Montori VM, Holmes DR, Bell MR, Curtis JP, Krumholz HM, Ting HH. Factors associated with 30-day readmission rates after percutaneous coronary intervention. *Arch Intern Med.* 2012;172:112-7.

8. Wasfy JH, Strom JB, O'Brien C, Zai AH, Luttrell J, Kennedy KF, Spertus JA, Zelevinsky K, Normand SL, Mauri L, Yeh RW. Causes of short-term readmission after percutaneous coronary intervention. *Circ Cardiovasc Interv.* 2014;7:97-103.

9. Yost GW, Puher SL, Graham J, Scott TD, Skelding KA, Berger PB, Blankenship JC. Readmission in the 30 days after percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2013;6: 237-44.

10. Yeh RW, Rosenfield K, Zelevinsky K, Mauri L, Sakhuja R, Shivapour DM, Lovett A, Weiner BH, Jacobs AK, Normand SL. Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention. *Circ Cardiovasc Interv.* 2012;5:227-36.

11. Kereiakes DJ. Return to sender hospital readmission after percutaneous coronary intervention. *J Am Coll Cardiol.* 2009;54: 908-10.

12. Laskey WK, Ricciardi MJ. 30-day readmission rate following percutaneous coronary intervention: much more than a binary variable. *JACC Cardiovasc Interv.* 2013;6:245-6.

13. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Sørensen HT, Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. *J Am Coll Cardiol.* 2007;50:463-70.

14. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. *Dan Med Bull.* 1999;46:263-8.

15. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. *Dan Med Bull.* 2006;53:441-9.

16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40:373-83.

17. Przybysz-Zdunek B, Ploch M, Pluta W, Dada M, Opolski G. All-cause readmission and repeat revascularization after percutaneous coronary intervention. *Cardiol J.* 2012;19:174-9. EuroIntervention 2018;14:926-934

18. Hannan EL, Zhong Y, Krumholz H, Walford G, Holmes DR Jr, Stamato NJ, Jacobs AK, Venditti FJ, Sharma S, King SB 3rd. 30-day readmission for patients undergoing percutaneous coronary interventions in New York state. *JACC Cardiovasc Interv.* 2011;4:1335-42.

19. Meadows ES, Bae JP, Zagar A, Sugihara T, Ramaswamy K, McCracken R, Heiselman D. Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis. *BMC Res Notes*. 2012;5:342. 20. Egholm G, Kristensen SD, Thim T, Olesen KK, Madsen M, Jensen SE, Jensen LO, Sorensen HT, Botker HE, Maeng M. Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. *J Am Coll Cardiol.* 2016;68:2622-32.

21. Ranasinghe I, Naoum C, Aliprandi-Costa B, Sindone AP, Steg PG, Elliott J, McGarity B, Lefkovits J, Brieger D; Australia-New Zealand GRACE. Management and outcomes following an acute coronary event in patients with chronic heart failure 1999-2007. *Eur J Heart Fail.* 2012;14:464-72.